[1] Bepler G,Begum M,Simon GR.Molecular analysis-based treatment strategies for non-small cell lung cancer[J].Cancer Control,2008,15(2):130-139. [2] 陆舜,虞永峰,纪文翔.2015年肺癌诊疗指南:共识和争议[J].解放军医学杂志,2016,41 (1):1-6. [3] Bach PB,Silvestri GA,Hanger M,et al.Screening for lung cancer:ACCP evidence based clinical practice guidelines (2nd edition)[J].Chest,2007,132(3 Suppl):69S-77S. [4] Siegel R,Naishadham D,Jemal A.Cancer statistics,2012[J]. CA Cancer J Clin,2012,62(5):283-298. [5] Poonacha TK, Go RS.Level of scientific evidence underlying recommendations arising from the National Comprehensive Cancer Network clinical practice guidelines[J]. J Clin Oncol,2011,29(2):186-191. [6] 薛慧,王文武,欧阳学农.S-1治疗晚期非小细胞肺癌的临床新进展[J].实用临床药学杂志,2011,15(3):125-128. [7] Carnio S,Novello S,Mele T,et al.Extending survival of stage Ⅳ non-small cell lung cancer[J].Semin Oncol, 2014,41(1):69-92. [8] Schiller JH,Harrington D,Belani CP,et al.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J].New England J Med,2002,346(2):92-98. [9] Socinski MA,Bondarenko I,Karaseva NA,et al.Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer:final results of a phase Ⅲ trial[J].J Clin Oncol,2012,30(17):2055-2062. [10] Yoshioka H,Okamoto I,Morita S,et al.Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer:updated results of the West Japan Oncology Group LETS study[J].Ann Oncol,2013,24(5):1326-1331. [11] Johnson DH, Fehrenbacher L,Novotny WF,et al.Randomized phase Ⅱ trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer[J].JClin Oncol, 2004,22(11):2184-2191. [12] Han B,Xiu Q,Wang H,et al.A multicenter,randomized,double-blind,placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer[J].J Clin Oncol,2011,6(6):1104-1109. [13] Garon EB,Ciuleanu TE,Arrieta O,et al.Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage Ⅳ non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL):a multicentre,double-blind,randomised phase 3 trial[J].Lancet,2014,384(9944):665-673. [14] Kim KL,Suh W.Apatinib,an inhibitor of vascular endothelial growth factor receptor 2,suppresses pathologic ocular neovascularization in mice[J].Invest Ophthalmol Visual Sci,2017,58(9):3592-3599. [15] Song Z,Yu X,Lou G,et al.Salvage treatment with apatinib for advanced non-small-cell lung cancer[J].Onco Targets Ther,2017,10:1821-1825. [16] Cao H,Wang J.Observation of herapeutic effect about advanced non-small cell lung cancer treated with apatinib mesylate tablets[J].Chin J Cancer Prevent Treatment,2017,24(7):468-470. [17] Ding L,Li QJ,You KY,et al.The use of apatinib in treating nonsmall-cell lung cancer:case report and review of literature[J].Medicine(Baltimore),2016,95(20):e3598. [18] Li J,Qin S,Xu J,Guo W,et al.Apatinib for chemotherapy-refractory advanced metastatic gastric cancer:results from a randomized,placebo-controlled,parallel-arm,phase Ⅱ trial[J].J Clin Oncol,2013,31(26):3219-3225. [19] 李媛.晚期非小细胞肺癌患者放疗前后肿瘤标志物变化与近期疗效的临床分析[J].中国实验诊断学,2017,21(8):1335-1337. |